Letztes “update” :
18/04/2024
Antibiotikum   Cefepime dihydrochloride  
Injektion
Augentropfen
Stabilität der Lösung Gemengestabilität Stabilitätbeeinflussende Faktoren Kompatibilitäten Applikationsart Literaturverzeichnis Pdf
   Chemische Struktur  

Handelsmarke   Handelsmarke     

Handelsnamen sind als beispielhaft anzusehen. Sonstige Bestandteile können je nach Hersteller oder Land verschieden sein

Aspime Venezuela
Avipim Türkei
Axépim Frankreich
Baxypime Mexiko
Cachepime Indien
Cefalospim Brasilien
Cefemin Kolumbien
Cefepem Brasilien
Cefepitax Brasilien
Cepim Italien
Cepimex Italien
Forcetex Ägypten
Maxcef Brasilien
Maxipime Belgien, Deutschland, Finnland, Griechenland, Italien, Kanada, Kolumbien, Luxemburg, Österreich, Peru, Polen, Portugal, Schweden, Spanien, Türkei, Ungarn, Vereinigte Staaten von Amerika
Nebamix Peru
Olpelinol Mexiko
Pimcef Peru
Pimerzen Mexiko
Roxipime Türkei
Unisef Türkei
Vipefime Mexiko
Literaturverzeichnis   Injektion   Literaturverzeichnis : Cefepime dihydrochloride  
Typ Veröffentlichung
182 Zeitung Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
251 Zeitung Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
873 Zeitung Das Gupta V, Maswoswe J, Bailey RE.
Stability of cefepime hydrochloride dextrose in 5% dextrose injection and 0.9% sodium chloride injection.
Int J Pharm Compound 1997 ; 1: 435-436.
921 Zeitung Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1046 Zeitung Stewart JT, Maddox FC, Warren FW.
Stability of cefepime hydrochloride in polypropylene syringes.
Am J Health-Syst Pharm 1999 ; 56: 1134.
1068 Zeitung Stewart JT, Warren FW, Maddox FC.
Stability of cefepime hydrochloride in polypropylene syringes at -20°C, 4°C and 22-24°C.
Am J Health-Syst Pharm 1999 ; 56: 457-459.
1290 Zeitung Williamson JC, Volles DF, Lynch PLM, Rogers PD, Haverstick DM.
Stability of cefepime in peritoneal dialysis solution.
Ann Pharmacotherapy 1999 ; 33: 906-909.
1410 Zeitung Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1605 Zeitung Stewart JT, Maddox FC, Warren FW.
Stability of cefepime hydrochloride injection and metronidazole in polyvinyl chloride bags at 4°C and 22-24°C.
Hosp Pharm 2000 ; 35: 1057-1064.
1625 Zeitung Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1626 Zeitung Ling J, Das Gupta V.
Stability of cefepime hydrochloride after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use.
Int J Pharm Compound 2001 ; 5: 151-152.
1648 Zeitung Schlesser V, Hecq J-D, Vanbeckbergen D, Jamart J, Galanti LM.
Effect of freezing, long-term storage, and microwave thawing on the stability of cefepime in 5% dextrose infusion polyvinyl chloride bags.
Int J Pharm Compound 2002 ; 6: 391-394.
1673 Zeitung Rabouan-Guyon M, Guet AF, Courtois PY, Barthes DMC.
Stability study of cefepime in different infusion solutions.
Int J Pharm 1997 ; 154: 185-190.
1712 Zeitung Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Zeitung Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Zeitung Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754 Zeitung Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1803 Zeitung Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1834 Zeitung Trissel LA, Xu QA.
Stability of cefepime hydrochloride in autodose infusion system bags.
Ann Pharmacotherapy 2003 ; 37, 6: 804-807.
1945 Zeitung Elwell RJ, Volino LR, Frye RF.
Stability of cefepime in icodextrin peritoneal dialysis solution.
Ann Pharmacotherapy 2004 ; 38: 2041-2044.
1982 Zeitung Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2042 Zeitung Viaene E, Chanteux H, Servais H, Mingeot-Leclerq MP, Tulkens PM.
Comparative stability studies of antipseudomonal ß-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).
Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2046 Zeitung Sprauten PF, Beringer PM, Louie ST, Synold TW, Gill MA.
Stability and antibacterial activity of cefepime during continuous infusion.
Antimicrob Agents Chemother 2003 ; 47: 1991-1994.
2134 Zeitung Fubara JO, Notari RE.
Influence of pH, temperature and buffers on cefepime degradation kinetics and stability predictions in aqueous solutions.
J Pharm Sci 1998 ; 87, 12: 1572-1576.
2141 Zeitung Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM.
Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.
J Antimicrob Chemother 2003 ; 51: 651-658.
2192 Zeitung Cochran BG, Sowinski KM, Fausel C, Overholser BR.
Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs.
Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2231 Zeitung de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S.
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247 Zeitung Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
3254 Zeitung Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3385 Zeitung Raverdi V, Ampe E, Hecq JD, Tulkens PM.
Stability and compatibility of vancomycin for administration by continuous infusion.
J Antimicrob Chemother 2013 ; 68: 1179-1182.
3416 Zeitung Csaba M, Boddu,S.H.S , Churchwell M.D.
Physical compatibility of sodium citrate with alcohol and cefepime.
Am J Health-Syst Pharm 2013 ; 70: 932-937
3520 Labor Cidomycin - Summary of product Chracteristics.
Sanofi 2011
3542 Zeitung Berti A.D, Hutson P.R, Schulz L.T, Webb A.P, Rose W.E.
Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion
Am J Health-Syst Pharm 2015 ; 72:390-395
3548 Labor Cefepime (Maxipime®) - Summary of Product caracteristics.
Bristol Myers Squibb 2007
3549 Labor Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3643 Labor Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics
Sanofi 2015
3674 Labor Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3827 Poster Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3879 Zeitung Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E.
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures.
Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3948 Zeitung Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424.
4055 Zeitung Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 Zeitung Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4254 Zeitung D'Huart E, Vigneron J, Demoré B.
Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs
Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4326 Zeitung Curti C, Harti Souab K, Lamy E, Mathias F, Bornet C, Guinard B, Fersing C, Primas N, Albanèse J, Vanelle P.
Stability studies of antipyocyanic beta-lactam antibiotics used in continuous infusion.
Pharmazie 2019 ; 74: 357-362.
4411 Zeitung Wilder A.G, Foushee J.A, Fox L.M, Navalle J, Wright A.M, Greer M.A.
Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions.
Int J Pharm Compound 2020 ;24,3:238-241.
4434 Zeitung Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4440 Zeitung Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M.
Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion.
Ann Nutr Metab 2018 ; 73: 227-233.
4465 Zeitung Foushee A, Meredith P, Fox Laura, Wilder A.
Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients.
Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4521 Zeitung Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B.
Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.
Pharmaceutical Technology in Hospital Pharmacy 2020
4528 Zeitung Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4634 Zeitung Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A.
Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy.
Antibiotics 2022 ;11,4: 458

  Mentions Légales